Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Carboplatin (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Olomorasib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Adenoid cystic carcinoma; Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Intestinal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms KRAS G12C
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 22 May 2025 According to an Eli Lilly and Company media release, updated results from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 07 Mar 2025 Planned number of patients changed from 550 to 540.
  • 07 Mar 2025 Planned End Date changed from 1 Jun 2026 to 1 Apr 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top